References
- Kahl, B.; Bailey, H.; Kim, K.; Smith, E.; Turman, N.; Smith, J.; Werndli, J.; McGovern, J.; Jumonville, A.; Williams, E.; Longo, W. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network study. Cancer Investig. 2005, 23, 13–18.
- Dumontet, C.; Sikic, B I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999, 17, 1061–1070., [PUBMED], [INFOTRIEVE]
- Jordan, M A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991, 51, 2212–2222. [PUBMED], [INFOTRIEVE]
- Jordan, M A.; Toso, R J.; Thrower, D.; Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 9552–9556. [PUBMED], [INFOTRIEVE], [CSA]
- Carbone, P P.; Bono, V.; Frei, E., III; Brindley, C O. Clinical studies with vincristine. Blood 1963, 21, 640–647. [PUBMED], [INFOTRIEVE]
- Carbone, P P.; Spurr, C.; Schneiderman, M.; Scotto, J.; Holland, J F.; Shnider, B. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 1968, 28, 811–822. [PUBMED], [INFOTRIEVE]
- Whitelaw, D M.; Kim, H S. Vincristine in the treatment of neoplastic disease. Can. Med. Assoc. J. 1964, 90, 1385–1389. [PUBMED], [INFOTRIEVE]
- Desai, D V.; Ezdinli, E Z.; Stutzman, L. Vincristine therapy of lymphomas and chronic lymphocytic leukemia. Cancer 1970, 26, 352–359.
- Younes, A.; Ayoub, J P.; Sarris, A.; Hagemeister, F.; North, L.; Pate, O.; McLaughlin, P.; Rodriguez, M A.; Romaguera, J.; Kurzrock, R.; Preti, A.; Bachier, C.; Smith, T.; Cabanillas, F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br. J. Haematol. 1997, 96, 328–332. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wilson, W H.; Chabner, B A.; Bryant, G.; Bates, S.; Fojo, A.; Regis, J.; Jaffe, E S.; Steinberg, S M.; Goldspiel, B R.; Cheson, B D. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J. Clin. Oncol. 1995, 13, 381–386. [PUBMED], [INFOTRIEVE]
- Press, O W.; LeBlanc, M.; O'Rourke, T J.; Gagnet, S.; Chapman, R A.; Balcerzak, S P.; Fisher, R I. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J. Clin. Oncol. 1998, 16, 574–578. [PUBMED], [INFOTRIEVE]
- Goss, P.; Stewart, A K.; Couture, F.; Klasa, R.; Gluck, S.; Kaizer, L.; Burkes, R.; Charpentier, D.; Palmer, M.; Tye, L.; Dulude, H. Combined results of two phase II studies of taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk. Lymphoma 1999, 34, 295–304. [PUBMED], [INFOTRIEVE], [CSA]
- Hahn, W C.; Weinberg, R A. Rules for making human tumor cells. N. Engl. J. Med. 2002, 347, 1593–1603. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Moon, E.; Lerner, A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G2/M arrest in a CLL cell line and apoptosis in primary CLL cells. Cancer Res. 2002, 62, 5711–5719. [PUBMED], [INFOTRIEVE]
- Vilpo, J A.; Koski, T.; Vilpo, L M. Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur. J. Haematol. 2000, 65, 370–378. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ling, Y.-H.; Tornos, C.; Perez-Soler, R. Phosphorylation of Bcl2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem. 1998, 273, 18984–18991. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yamamoto, K.; Ichijo, H.; Korsmeyer, S J. Bcl2 is phosphorylated and inactivated by an Ask1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell. Biol. 1999, 19, 8469–8478. [PUBMED], [INFOTRIEVE]